Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus in Individuals With PTEN Mutations
NCT02991807Phase 2Completed
- Sponsor
- Boston Children's Hospital
- Start
- Jun 2017
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in PTEN hamartoma tumor syndrome (PHTS) comparing RAD001 Arm with Placebo Arm (2 arms). Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 6 months. Started Jun 2017; status: completed.
02
Drugs
everolimus
03
Conditions
PTEN hamartoma tumor syndrome (PHTS)
Beyond the preview
Go deeper on NCT02991807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02991807.